A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus

Summary

The study hypotheses to be tested in this study are: * Conversion to everolimus at 3 months post-transplantation is safe and effective; * Accurate noninvasive molecular diagnostic tests can replace biopsy at 3 months pre-conversion (for the diagnosis of subclinical cellular and/or humoral rejection, tissue fibrosis and calcineurin inhibitor-induced nephrotoxicity) in kidney transplant recipients; * Follow-up biopsy at 12 months post-conversion (for the diagnosis of tissue fibrosis) can be replaced with accurate noninvasive molecular diagnostic tests in kidney transplant recipients.

Timeline

Start

2012-02

Primary completion

2014-07

Completion

2014-07

Drugs

Indications